The 2009 BioFirst Commercialisation Award
The annual BioFirst Commercialisation Award rewards outstanding commercialisation efforts by a NSW biotechnology or medical device company which has been assisted under DSRD's BioBusiness programs.
Commercialisation success can be demonstrated through achievements in areas such as investment, partnering, licensing, sales and exports
BioBusiness programs include Proof of Concept; Non Research Establishment Costs; High Growth BioBusiness; BioFirst Biotechnology Precinct; and International Marketing and Promotion.
The BioFirst Commercialisation Award is presented to the NSW biotechnology or medical device company which demonstrates the best case for achieving international success with either a technology, product or service.
The winning applicant will need to demonstrate that the Award will significantly enhance their opportunity for international success.
The Award's objective is to assist the winner with their international development plans. Award prizes will include a cash prize toward international business development activities and expert advisory services on commercialisation issues.
The winner of the 2009 BioFirst Commercialisation Award will be selected by a judging panel made up of BioFirst Commercialisation Award supporters including Merck Sharpe and Dohme (Australia); PricewaterhouseCoopers; Allens Arthur Robinson; and Invetech.
You can find out about previous winners here.
Timing and Selection Process
Applications will be judged purely on the information contained in the Application Form. No supplementary documents, such as references, will be admitted. Remember that this is a competition, and it is up to you to promote your company's achievements and excellence as succinctly as possible.
Short-listed applicants will be invited to make a presentation to the Judging Panel.
The BioFirst Commercialisation Award winner for 2009 will be announced in July this year.
These programs are currently under review.